![]() The present study will first explore the clinical efficacy and safety of FMT for treating SIBO to provide a basis for the clinical application of FMT in the treatment of SIBO. However, the efficacy of FMT treatment for such diseases has not yet been investigated. Based on the fact that SIBO is mainly due to the imbalance of intestinal microbiota, we believe that the use of FMT will be of great help in the treatment of SIBO patients. 2015103040414) and has been successfully applied in clinical practice. In our previous work, an encapsulated FMT, named the “intestinal microbiota capsule”, was developed by our team (national invention patent No. El-Salhy reported that FMT is a promising tool for managing IBS. A published systematic review demonstrated that FMT has the potential to treat ulcerative colitis. Compared to probiotics, FMT has more advantages for patients because the transplantation of fecal microbiota is an integral transplantation of intestinal microecology and is “an organ” that humans can truly share, with high safety which would not elicit immune response or rejection like other means of transplanted organ. It has been proposed as an effective therapy to restore the gut microbiota barrier by transplanting functional gut microbiota from healthy donors to patients. For years, FMT has been used as an effective treatment for CDI, as well as other recurrent or refractory gastrointestinal disease. Recently, applying fecal microbiota transplantation (FMT) to gastrointestinal diseases has re-emerged and gained increasing attention from medical researchers. Beyond that, probiotics can be used to help restore the gut microbial ecosystem, with a curative effect with the antibiotic of 62.8%. SIBO patients are often rescripted with antibiotics (i.e., rifaximin, norfloxacin, metronidazole, trimethoprim-sulfamethoxazole, etc.), nonetheless, the efficacy of norfloxacin is approximately 37.5%, and they cannot be used repeatedly for long periods of time. Recently, multiple studies have confirmed that SIBO is correlated with irritable bowel syndrome, liver cirrhosis and small intestinal tumors, the presence of SIBO has influences on the progression and prognosis of the abovementioned diseases, both directly and indirectly. SIBO is a common and frequent problem in outpatient practice, especially in irritable bowel syndrome (IBS) patients. Small intestinal bacterial overgrowth (SIBO) is induced by excessive growth of bacteria in the small intestine and is mainly accompanied with a myriad of gastrointestinal symptoms, including flatulence, dyspepsia, and diarrhea, it is associated with marked adverse effects on quality of life and elevated costs in health care expenditures. This study was retrospectively registered with the Chinese Clinical Trial registry on 2019.7.10 (ID: ChiCTR1900024409, ). This study suggests that applying FMT for patients with SIBO can alleviate gastrointestinal symptoms, indicating that FMT may be a promising and novel therapeutic regimen for SIBO. The gut microbiota diversity of FMT group had a significant increase, while placebo group showed none. Gastrointestinal symptoms significantly improved in SIBO patients after treatment with FMT compared to participants in placebo group. Measurements including the lactulose hydrogen breath test gastrointestinal symptoms, as well as fecal microbiota diversity were assessed before and after FMT therapy. ![]() All participants were randomized in two groups, and were given FMT capsule or placebo capsules once a week for 4 consecutive weeks. In this trial, 55 SIBO patients were enrolled. However, whether FMT could be applied as a routine SIBO treatment has not been investigated. Fecal microbiota transplantation (FMT) has been applied as an effective tool for reestablishing the structure of gut microbiota. Small intestinal bacterial overgrowth (SIBO) is characterized by the condition that bacteria overgrowth in the small intestine.
0 Comments
Leave a Reply. |